Brimonidine 0.2% administered twice daily is an effective and safe ocular hypotensive agent that maintains IOP-lowering in chronic use.To evaluate the prophylactic effect of levobunolol 0.5%, timolol 0.5%, or vehicle in reducing the incidence of postoperative intraocular pressure (IOP) spikes of 5 and 10 mm Hg or more in patients having neodymium:YAG (Nd:YAG) laser posterior capsulotomy.

Visits were conducted before the study, at baseline, at weeks 2 and 6, and at months 3, 6, 9, and 12.

COVID-19 is an emerging, rapidly evolving situation.

The 81 patients (81 eyes), who underwent Nd:YAG laser posterior capsulotomy, were allocated to two treatment groups.

With the exception of ocular allergy (in 11.5% of patients using brimonidine and less than 1% using timolol), fewer than 3% of patients in either treatment group withdrew from the study prematurely as a result of a specific adverse event. The differences in the mean IOPs were < or = 0.26 mm Hg and the mean change from baseline IOP was < or = 0.35 mm Hg at all follow-up time points. Mean percentual postoperative IOP reduction was detected in the apraclonidine group -24.7 +/- 15.5% (9.8 +/- 2.6 mmHg), in the brimonidine group -8.9 +/- 15.5% (10.1 +/- 1.7 mmHg), in the dorzolamide group -6.9 +/- 20.3% (12.1 +/- 2.8 mmHg), in the latanoprost group -0.4 +/- 25.9% (12.1 +/- 2.9 mmHg) and in timolol group -16.2 +/- 14.1% (10.3 +/- 1.7 mmHg). The complications included increases in intraocular pressure in 28 eyes. The patients were randomly divided into two groups of 50 patients. Med. Postoperative IOP elevations of 5 mm Hg or more occurred in 13% of Fifty four eyes of 54 patients undergoing Nd-YAG laser posterior capsulotomy were randomly assigned to pretreatment with either 125 mg of oral acetazolamide (group A) or placebo (group B).

We found that pretreatment with a low dose of acetazolamide is highly effective in preventing IOP elevation following Nd-YAG laser posterior capsulotomy.Yan ke xue bao = Eye science / "Yan ke xue bao" bian ji bu the intraocular pressure was the lowest 2 hours after capsulotomy.
2007 Oct;23(5):481-6. doi: 10.1089/jop.2007.0042.Surv Ophthalmol. Control and pilocarpine had a percentual IOP increase after 2 hours of 8.7 +/- 19.1% (13.5 +/- 3.2 mmHg) and 1.2 +/- 26.3% (12.5 +/- 3.6 mmHg) respectively.

When normalized for concentration differences between the 2 formulations, AH concentrations were similar (P=0.85). The brimonidine group had more ocular allergy, oral dryness and conjunctival follicles. Levobunolol 0.5% or timolol 0.5% administered preoperatively and again in the evening after Nd:YAG laser capsulotomy effectively blunted the IOP rise that frequently follows laser surgery.Reported rates of posterior capsule opacification (PCO) vary widely and are based on various definitions of PCO, varying lengths and intervals of follow-up, and the use of different surgical techniques, intraocular lens (i.o.l.)

Brimonidine is safe and effective in the long-term lowering of intraocular pressure in patients with glaucoma or ocular hypertension, with efficacy comparable to that of timolol but without a notable negative chronotropic effect on the heart.The prophylactic effect of topical 0.5% levobunolol on intraocular pressure (IOP) elevations after neodymium:YAG (Nd:YAG) laser posterior capsulotomies and extracapsular cataract extractions (ECCEs) was investigated in two separate, double-masked, placebo-controlled studies. Patients (n = 926) instilled either brimonidine tartrate 0.2% or timolol maleate 0.5% twice daily. The median age of eligible patients who did not participate in the study was higher than that of enrolled patients (79.6 versus 74.4 years; P =.0005). The number, type, and location of retinal breaks were recorded. Mean intraocular pressure (IOP) peaked by three hours with a mean increase of 13 mmHg, remained elevated by 5 mmHg at 24 hours but returned to baseline by one week. This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine.

The timolol group had significantly lower mean heart rate compared to baseline.

This was a double-masked, randomized, placebo-controlled clinical study in 60 patients who underwent Nd:YAG laser posterior capsulotomy after extracapsular cataract extraction. Change in extracapsular barrier efficiency as measured by fluorophotometry. Patients receiving timolol experienced significant decreases in heart rate (P < .001) from baseline at all follow-up visits. eCollection 2019 Mar.Oman J Ophthalmol.